A PPARγ agonist
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Rosiglitazone (potassium salt)

Item No. 71742

Technical Information
Formal Name
5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione, monopotassium salt
CAS Number
316371-84-3
Molecular Formula
C18H18N3O3S • K
Formula Weight
Purity
≥98%
Formulation
A crystalline solid
DMF: >25 mg/mlDMSO: >25 mg/mlDMSO:PBS (7.2 pH) (1:3): 500 µg/mlEthanol: 2 mg/mlH2O: 1 mg/ml
λmax
247 nm
SMILES
CN(CCOC1=CC=C(CC2SC([N-]C2=O)=O)C=C1)C3=NC=CC=C3.[K+]
InChi Code
InChI=1S/C18H19N3O3S.K/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15;/h2-9,15H,10-12H2,1H3,(H,20,22,23);/q;+1/p-1
InChi Key
RWOGCLSZSSKLEN-UHFFFAOYSA-M
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Rosiglitazone is an agonist of peroxisome proliferator-activated receptor γ (PPARγ).1 It activates PPARγ1 and PPARγ2 in reporter assays (EC50s = 30 and 100 nM, respectively). Rosiglitazone selectively activates chimeras containing the ligand-binding domains (LBDs) of PPARγ over PPARα and PPARδ in a cell-based reporter assay at 10 mM. It induces differentiation of C3H10T1/2 stem cells into adipocytes when used at a concentration of 1 µM. Rosiglitazone is also an inhibitor of long-chain acyl-CoA synthetase 4 (ACSL4; IC50 = 0.5 µM), inhibits RSL3-induced ferroptosis in Pfa1 cells and Pparg knockout (KO) cells, and increases survival in a Gpx4 KO mouse model of ferroptosis when used at a concentration of 0.0125 mg/ml in the drinking water.2,3 It decreases hemoglobin A1c (HbA1c) and fasting blood glucose levels in a rat model of type 2 diabetes induced by streptozotocin (STZ; Item No. 13104) and a high-carbohydrate and high-fat diet when administered at a dose of 4 mg/kg.4 Formulations containing rosiglitazone have been used to improve glycemic control in the treatment of type 2 diabetes.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Lehmann, J.M., Moore, L.B., Smith-Oliver, T.A., et alAn antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). The Journal of Biological Chemisty 270(22), 12953-12956 (1995).

    2. Kim, J.-H., Lewin, T.M., and Coleman, R.A. Expression and characterization of recombinant rat Acyl-CoA synthetases 1, 4, and 5. Selective inhibition by triacsin C and thiazolidinediones. The Journal of Biological Chemisty 276(27), 24667-24673 (2001).

    3. Doll, S., Proneth, B., Tyurina, Y.Y., et alACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 13(1), 91-98 (2017).

    4. Zhou, J.Y., Zhou, S.W., Zhang, K.B., et alChronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats. Biol. Pharm. Bull. 31(6), 1169-1176 (2008).

    Product Citations

    Knoll, M., Winther, S., Natarajan, A., et alSYK kinase mediates brown fat differentiation and activation. Nat. Commun. 8(1), 2115 (2017).